Literature DB >> 10695735

Molecular pathogenesis of multiple sclerosis.

A Bar-Or1, E M Oliveira, D E Anderson, D A Hafler.   

Abstract

Multiple sclerosis (MS) is best understood as an inflammatory disease of the central nervous system (CNS) white matter characterized by demyelination, focal T cell and macrophage infiltrates, axonal injury and loss of neurological function. Our current understanding invokes proinflammatory cells and mediators that may be triggered by environmental factors to mediate disease in a genetically susceptible host. Five major themes which have been associated with the pathogenesis of MS lesions will be discussed: (1) The differential activation states of myelin-reactive T cells from MS patients vs. normal individuals, (2) the selective expression of chemokines, adhesion molecules and matrix metalloproteinases, (3) the proposed roles of the B7 costimulatory pathway, (4) the proinflammatory cytokines and (5) the role of molecular mimicry.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10695735     DOI: 10.1016/s0165-5728(99)00193-9

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  20 in total

Review 1.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  Xu Zhang; Raymond Hupperts; Marc De Baets
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models.

Authors:  Dimitry N Krementsov; Tina M Thornton; Cory Teuscher; Mercedes Rincon
Journal:  Mol Cell Biol       Date:  2013-07-29       Impact factor: 4.272

4.  High fat diet exacerbates neuroinflammation in an animal model of multiple sclerosis by activation of the Renin Angiotensin system.

Authors:  Silke Timmermans; Jeroen F J Bogie; Tim Vanmierlo; Dieter Lütjohann; Piet Stinissen; Niels Hellings; Jerome J A Hendriks
Journal:  J Neuroimmune Pharmacol       Date:  2013-09-26       Impact factor: 4.147

Review 5.  Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date.

Authors:  Allison B Reiss; Elzbieta Wirkowski
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.

Authors:  Alberto Chiarugi
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 7.  Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.

Authors:  D S Goodin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.

Authors:  Lori Mayer; Mary Kay Fink; Carrie Sammarco; Lisa Laing
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

9.  Absence of the cellular prion protein exacerbates and prolongs neuroinflammation in experimental autoimmune encephalomyelitis.

Authors:  Shigeki Tsutsui; Jennifer N Hahn; Trina A Johnson; Zenobia Ali; Frank R Jirik
Journal:  Am J Pathol       Date:  2008-10       Impact factor: 4.307

10.  Early stage and long term treatment of multiple sclerosis with interferon-beta.

Authors:  Angela Applebee; Hillel Panitch
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.